145 related articles for article (PubMed ID: 14529397)
1. Potential new targets for antithrombotic therapy.
Gruber A; Hanson SR
Curr Pharm Des; 2003; 9(28):2367-74. PubMed ID: 14529397
[TBL] [Abstract][Full Text] [Related]
2. New antithrombotic strategies for resistant thrombotic processes.
Harker LA
J Clin Pharmacol; 1994 Jan; 34(1):3-16. PubMed ID: 8132848
[TBL] [Abstract][Full Text] [Related]
3. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
4. Potent Thrombolytic Effect of
Martinez de Lizarrondo S; Gakuba C; Herbig BA; Repessé Y; Ali C; Denis CV; Lenting PJ; Touzé E; Diamond SL; Vivien D; Gauberti M
Circulation; 2017 Aug; 136(7):646-660. PubMed ID: 28487393
[TBL] [Abstract][Full Text] [Related]
5. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives in the treatment of thrombotic disorders.
Drouet L; Caen JP
Semin Thromb Hemost; 1989 Apr; 15(2):111-22. PubMed ID: 2665082
[TBL] [Abstract][Full Text] [Related]
8. Advances in antithrombotic agents.
Chakrabarti R; Das SK
Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):175-85. PubMed ID: 17630943
[TBL] [Abstract][Full Text] [Related]
9. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice.
Teng CM; Wu CC; Ko FN; Lee FY; Kuo SC
Eur J Pharmacol; 1997 Feb; 320(2-3):161-6. PubMed ID: 9059849
[TBL] [Abstract][Full Text] [Related]
10. Blood coagulation: hemostasis and thrombin regulation.
Tanaka KA; Key NS; Levy JH
Anesth Analg; 2009 May; 108(5):1433-46. PubMed ID: 19372317
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism.
Kitzen JM; McCallum JD; Harvey C; Morin ME
J Cardiovasc Pharmacol; 1991 Dec; 18(6):777-90. PubMed ID: 1725888
[TBL] [Abstract][Full Text] [Related]
14. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
15. Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.
Bonnard T; Tennant Z; Niego B; Kanojia R; Alt K; Jagdale S; Law LS; Rigby S; Medcalf RL; Peter K; Hagemeyer CE
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159824
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
[TBL] [Abstract][Full Text] [Related]
17. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
Yamamoto J; Inoue N; Otsui K; Ishii H; Gorog DA
Thromb Res; 2014 May; 133(5):919-26. PubMed ID: 24613697
[TBL] [Abstract][Full Text] [Related]
18. Future Antithrombotic Therapies in Cardiology.
Bäuml M; Hilgendorf I
Hamostaseologie; 2018 Nov; 38(4):236-239. PubMed ID: 30267387
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.
Gruber A; Harker LA; Hanson SR; Kelly AB; Griffin JH
Circulation; 1991 Dec; 84(6):2454-62. PubMed ID: 1835678
[TBL] [Abstract][Full Text] [Related]
20. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
